- Home
- CDT vs WLGS Comparison
CDT vs WLGS Comparison
Compare CDT & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- WLGS
- Stock Information
- Founded
- CDT 2019
- WLGS 1981
- Country
- CDT United States
- WLGS Hong Kong
- Employees
- CDT N/A
- WLGS N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- WLGS Engineering & Construction
- Sector
- CDT Health Care
- WLGS Consumer Discretionary
- Exchange
- CDT Nasdaq
- WLGS Nasdaq
- Market Cap
- CDT 5.3M
- WLGS 4.2M
- IPO Year
- CDT N/A
- WLGS 2023
- Fundamental
- Price
- CDT $0.40
- WLGS $0.17
- Analyst Decision
- CDT
- WLGS
- Analyst Count
- CDT 0
- WLGS 0
- Target Price
- CDT N/A
- WLGS N/A
- AVG Volume (30 Days)
- CDT 3.1M
- WLGS 1.6M
- Earning Date
- CDT 05-20-2025
- WLGS 05-20-2025
- Dividend Yield
- CDT N/A
- WLGS N/A
- EPS Growth
- CDT N/A
- WLGS N/A
- EPS
- CDT N/A
- WLGS 0.02
- Revenue
- CDT N/A
- WLGS $7,272,879.00
- Revenue This Year
- CDT N/A
- WLGS N/A
- Revenue Next Year
- CDT N/A
- WLGS N/A
- P/E Ratio
- CDT N/A
- WLGS $9.12
- Revenue Growth
- CDT N/A
- WLGS 66.93
- 52 Week Low
- CDT $0.51
- WLGS $0.15
- 52 Week High
- CDT $350.00
- WLGS $9.66
- Technical
- Relative Strength Index (RSI)
- CDT 31.06
- WLGS 28.36
- Support Level
- CDT $0.37
- WLGS $0.15
- Resistance Level
- CDT $0.57
- WLGS $0.19
- Average True Range (ATR)
- CDT 0.05
- WLGS 0.02
- MACD
- CDT 0.01
- WLGS 0.13
- Stochastic Oscillator
- CDT 13.89
- WLGS 27.47
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.